1. Home
  2. SNPS vs SNY Comparison

SNPS vs SNY Comparison

Compare SNPS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNPS
  • SNY
  • Stock Information
  • Founded
  • SNPS 1986
  • SNY 1994
  • Country
  • SNPS United States
  • SNY France
  • Employees
  • SNPS N/A
  • SNY N/A
  • Industry
  • SNPS EDP Services
  • SNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNPS Technology
  • SNY Health Care
  • Exchange
  • SNPS Nasdaq
  • SNY Nasdaq
  • Market Cap
  • SNPS 112.2B
  • SNY 113.4B
  • IPO Year
  • SNPS 1992
  • SNY N/A
  • Fundamental
  • Price
  • SNPS $598.14
  • SNY $46.50
  • Analyst Decision
  • SNPS Strong Buy
  • SNY Buy
  • Analyst Count
  • SNPS 14
  • SNY 3
  • Target Price
  • SNPS $630.71
  • SNY $65.00
  • AVG Volume (30 Days)
  • SNPS 1.0M
  • SNY 2.7M
  • Earning Date
  • SNPS 09-09-2025
  • SNY 10-24-2025
  • Dividend Yield
  • SNPS N/A
  • SNY 3.44%
  • EPS Growth
  • SNPS 51.03
  • SNY 118.56
  • EPS
  • SNPS 13.85
  • SNY 8.65
  • Revenue
  • SNPS $6,221,316,000.00
  • SNY $53,714,621,258.00
  • Revenue This Year
  • SNPS $14.94
  • SNY $2.01
  • Revenue Next Year
  • SNPS $18.70
  • SNY $6.82
  • P/E Ratio
  • SNPS $69.14
  • SNY $10.62
  • Revenue Growth
  • SNPS 7.50
  • SNY 15.65
  • 52 Week Low
  • SNPS $365.74
  • SNY $44.73
  • 52 Week High
  • SNPS $651.73
  • SNY $60.12
  • Technical
  • Relative Strength Index (RSI)
  • SNPS 48.50
  • SNY 38.50
  • Support Level
  • SNPS $584.00
  • SNY $45.04
  • Resistance Level
  • SNPS $614.63
  • SNY $50.38
  • Average True Range (ATR)
  • SNPS 12.60
  • SNY 0.70
  • MACD
  • SNPS -3.32
  • SNY -0.42
  • Stochastic Oscillator
  • SNPS 33.48
  • SNY 22.26

About SNPS Synopsys Inc.

Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: